We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

81 hedge funds and large institutions have $222M invested in AEON Biopharma in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 3

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

11% more funds holding

Funds holding: 73 → 81 (+8)

8% more capital invested

Capital invested by funds: $205M → $222M (+$17.1M)

0.08% more ownership

Funds ownership: 1.09% → 1.17% (+0.08%)

Holders
81
Holders Change
+8
Holders Change %
+10.96%
% of All Funds
1.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
18
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$4.55M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$2.57M
3
Calamos Advisors
Calamos Advisors
Illinois
+$2.46M
4
MF
Magnetar Financial
Illinois
+$1.81M
5
WRBC
W.R. Berkley Corp
Connecticut
+$955K

Top Sellers

Rank Fund Capital Flow
1
PMAM
Picton Mahoney Asset Management
Ontario, Canada
-$3.43M
2
TCM
Tegean Capital Management
New York
-$491K
3
UOC
UBS O'Connor
Illinois
-$470K
4
Citigroup
Citigroup
New York
-$245K
5
OCAM
Owl Creek Asset Management
New York
-$245K
Name Holding Trade Value Shares
Change 		Change in
Stake
DFCM
51
Dark Forest Capital Management
Puerto Rico
$602K +$356K +503 +145%
WAM
52
Wolverine Asset Management
Illinois
$563K +$26.2K +37 +5%
HighTower Advisors
53
HighTower Advisors
Illinois
$517K – – –
HF
54
HRT Financial
New York
$505K – – –
Susquehanna International Group
55
Susquehanna International Group
Pennsylvania
$503K +$502K +709 New
COPPSERS
56
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$493K – – –
SCM
57
Segantii Capital Management
Hong Kong
$493K – – –
CCM
58
Context Capital Management
California
$489K – – –
AR
59
Advisory Research
Illinois
$469K – – –
Blackstone Inc
60
Blackstone Inc
New York
$395K – – –
RCM
61
Rivernorth Capital Management
Florida
$394K – – –
NAM
62
Nexpoint Asset Management
Texas
$392K – – –
LA
63
Linden Advisors
New York
$368K – – –
BCM
64
Basso Capital Management
Connecticut
$363K -$14.2K -20 -4%
ACA
65
Arena Capital Advisors
California
$302K – – –
CCM
66
Cinctive Capital Management
New York
$246K – – –
AGC
67
Angelo Gordon & Co
New York
$246K +$246K +347 New
RCM
68
Robinson Capital Management
Michigan
$243K – – –
TI
69
Tidal Investments
Wisconsin
$243K – – –
BFM
70
Boothbay Fund Management
New York
$221K +$221K +312 New
KKRC
71
Kohlberg Kravis Roberts & Co
New York
$219K – – –
Barclays
72
Barclays
United Kingdom
$203K +$203K +286 New
FTUS
73
Flow Traders U.S.
New York
$186K +$186K +263 New
AA
74
Ancora Advisors
Ohio
$165K – – –
Geode Capital Management
75
Geode Capital Management
Massachusetts
$145K +$145K +205 New
1 2
3
4

AEON Hedge Fund Activity: Q3 2022 in Review

81 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q3 2022, worth a combined $222M — up 8.3% from $205M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AEON positions and 5 closed out — a net gain of 8 holders — while 18 added to existing stakes and 3 trimmed.

The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $4.55M. The largest seller was Picton Mahoney Asset Management, exiting entirely with an estimated $3.43M sold.

  • 81 institutional investors held AEON Biopharma (AEON) as of Q3 2022, up from 73 in Q2 2022.
  • Funds reported $222M of AEON Biopharma stock for Q3 2022, up 8.3% quarter-over-quarter.
  • 13 funds opened new AEON Biopharma positions in Q3 2022 and 5 closed out, a net change of +8 holders.
  • The largest AEON Biopharma buyer in Q3 2022 was BNP Paribas Financial Markets, an estimated $4.55M added.
  • The largest AEON Biopharma seller in Q3 2022 was Picton Mahoney Asset Management, an estimated $3.43M sold.

Based on aggregated 13F filings for Q3 2022.